To study the role of IGF2BP3 in d-ICD treatment, we first analyzed intrinsic IGF2BP3 expression in several HCC cell lines to select appropriated cell lines for the following analysis, and CD133 expression in different cell lines was also taken in consideration [4] (Supplementary Figure S2). The gene discussed is IGF2BP3; the disease is hepatocellular carcinoma.